Shouldn't dr lal path labs have a rub off effect of the madrush over subscription that Thyrocare has seen?
Thyro lists on Monday perhaps, Dr Lal is priced at about 65 p/e and Thyro IPO was 45 p/e, once thyro lists it can easily cross the valuation of Lal looking at the demand in the IPO... would be interesting to see a Big rub off effect on Monday?
Thyro lists on Monday perhaps, Dr Lal is priced at about 65 p/e and Thyro IPO was 45 p/e, once thyro lists it can easily cross the valuation of Lal looking at the demand in the IPO... would be interesting to see a Big rub off effect on Monday?
